+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Global Forecast 2026-2032- Product Image
Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Global Forecast 2026-2032- Product Image
Sale

Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082406
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diagnostic Radiopharmaceuticals for Alzheimer Disease Market is projected to reach USD 2.21 Billion in 2026. It is expected to continue growing at a CAGR of 10.91%, reaching USD 4.12 Billion by 2032.

Diagnostic Radiopharmaceuticals for Alzheimer Disease: Executive Overview

Diagnostic radiopharmaceuticals support Alzheimer disease assessment by enabling visualization of pathological features such as amyloid and tau deposition through positron emission tomography. Their clinical value is strongest when imaging is integrated with cognitive evaluation, neurological examination, structural imaging, and laboratory biomarkers. Adoption depends on validated clinical utility, appropriate patient selection, reimbursement, radiopharmacy capacity, and access to PET infrastructure.

Clinical Integration Is Reshaping the Diagnostic Landscape

The landscape is shifting from symptom-based assessment toward biologically informed diagnosis and disease staging. Greater emphasis on earlier recognition, differential diagnosis, and treatment eligibility is increasing the importance of standardized imaging protocols and multidisciplinary interpretation. At the same time, regulatory expectations, radiation-safety requirements, tracer logistics, and the need for confirmatory testing continue to shape implementation. Expansion will therefore depend not only on tracer availability, but also on coordinated diagnostic pathways and trained personnel.

Artificial Intelligence Strengthens Image Interpretation and Workflow

Artificial intelligence is contributing to automated image quantification, abnormality detection, quality control, and workflow prioritization. These tools may improve reproducibility and help reduce interpretation variability, particularly where specialist readers are limited. However, clinical deployment requires representative validation datasets, transparent performance assessment, human oversight, cybersecurity controls, and compatibility with local imaging systems. AI is most useful as a decision-support layer rather than a substitute for clinical judgment.

Regional Differences Reflect Infrastructure, Reimbursement, and Workforce Readiness

North America generally benefits from established PET networks, specialized neurology services, and clearer integration of biomarker testing, although reimbursement and geographic access remain important constraints. Europe combines advanced research capacity with varied national reimbursement, regulatory, and referral structures. Asia-Pacific includes highly capable health systems alongside areas with limited PET access, making workforce development and centralized imaging pathways especially relevant. Latin America faces uneven infrastructure, affordability, and radiopharmacy distribution. The Middle East is investing in specialized healthcare capacity but continues to experience differences among national systems. Africa has significant unmet diagnostic need, while limited imaging infrastructure, tracer availability, and specialist coverage constrain routine use.

Economic and Institutional Groups Show Uneven Readiness

ASEAN markets differ substantially in PET availability, regulatory maturity, and specialist capacity, favoring regional training and referral networks. BRICS members include large patient populations and expanding research capabilities, but access and reimbursement remain uneven. The European Union benefits from shared scientific and regulatory collaboration while retaining national differences in payment and service delivery. G7 countries generally possess stronger research, imaging, and clinical infrastructures, though cost-effectiveness and equitable access remain priorities. GCC states are developing advanced diagnostic capacity, often through centralized services. NATO members span mature and emerging systems, making interoperability, procurement resilience, and workforce mobility relevant considerations.

Country-Level Priorities Range from Capacity Expansion to Standardization

Australia and Canada must address geographic concentration of specialized imaging. Brazil, Mexico, India, and Russia face variation in access, reimbursement, and radiopharmacy infrastructure across large territories. China and Japan have substantial healthcare and research capacity, with continued emphasis on standardization, workforce development, and integration into aging-care pathways. South Korea is well positioned for technology-enabled imaging but must sustain clinical validation and equitable access. France, Germany, Italy, Spain, and the United Kingdom combine advanced clinical capabilities with differing reimbursement, referral, and health-technology-assessment requirements. The United States has extensive PET capability, but affordability, coverage policy, and regional access remain central implementation issues.

Industry Leaders Should Build Evidence, Access, and Operational Resilience Together

Leaders should prioritize evidence that connects imaging results with clinical decisions, patient outcomes, and treatment selection. They should establish standardized acquisition and interpretation protocols, invest in reader training, and use AI only after rigorous local validation. Partnerships with hospitals, radiopharmacies, regulators, and payers can improve referral pathways and reimbursement readiness. Operational planning should address isotope supply, production redundancy, dose handling, scheduling, data interoperability, and quality assurance. Access strategies should include hub-and-spoke services, tele-radiology support, and affordability measures suited to each healthcare system.

Methodology: Evidence-Led Synthesis of Clinical and Health-System Factors

This executive summary uses the defined market scope-diagnostic radiopharmaceuticals for Alzheimer disease-and synthesizes established considerations from clinical practice, diagnostic imaging, radiopharmacy operations, regulation, reimbursement, health-system infrastructure, and artificial-intelligence implementation. Geographic and group-level observations are framed as qualitative comparisons rather than numerical estimates. The assessment distinguishes validated clinical requirements from implementation considerations and avoids unsupported claims about market size, shares, or forecasts.

Successful Adoption Depends on Clinical Utility and Equitable Delivery

Diagnostic radiopharmaceuticals can strengthen biologically informed Alzheimer disease assessment when used within appropriate clinical pathways and interpreted alongside other evidence. The next phase of progress will depend on reproducible standards, validated AI support, reliable radiopharmaceutical supply, trained professionals, sustainable reimbursement, and broader geographic access. Organizations that align scientific evidence with practical delivery requirements will be best positioned to improve diagnostic confidence while supporting responsible and equitable use.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Radiotracer Type
7.1. Introduction
7.2. Carbon 11 Pittsburgh Compound B
7.3. Fluorine 18 Florbetaben
7.4. Fluorine 18 Florbetapir
7.5. Fluorine 18 Flutemetamol
8. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Radioisotope
8.1. Introduction
8.2. Carbon 11
8.3. Fluorine 18
9. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Application
9.1. Introduction
9.2. Clinical Imaging
9.3. Research Imaging
10. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by End User
10.1. Introduction
10.2. Diagnostic Centers
10.3. Hospitals
10.4. Research Laboratories
11. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Third Party Distribution
12. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Avid Radiopharmaceuticals, Inc.
16.2. Bracco Imaging S.p.A.
16.3. Curium Pharma, LLC
16.4. Eli Lilly and Company
16.5. Fujifilm Holdings Corporation
16.6. GE Healthcare Limited
16.7. Ion Beam Applications S.A.
16.8. Life Molecular Imaging, Inc.
16.9. Navidea Biopharmaceuticals, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, Years Considered for the Study
FIGURE 2. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, Research Design
FIGURE 3. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, Research Framework
FIGURE 4. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, Data Triangulation
FIGURE 5. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2025 vs 2032 (%)
FIGURE 7. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2025 vs 2032 (%)
FIGURE 9. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Segmentation & Coverage
TABLE 2. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 3. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 4. Global Carbon 11 Pittsburgh Compound B Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Carbon 11 Pittsburgh Compound B Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Carbon 11 Pittsburgh Compound B Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Fluorine 18 Florbetaben Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Fluorine 18 Florbetaben Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Fluorine 18 Florbetaben Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Fluorine 18 Florbetapir Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Fluorine 18 Florbetapir Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Fluorine 18 Florbetapir Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Fluorine 18 Flutemetamol Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Fluorine 18 Flutemetamol Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Fluorine 18 Flutemetamol Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 17. Global Carbon 11 Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Carbon 11 Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Carbon 11 Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Fluorine 18 Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Fluorine 18 Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Fluorine 18 Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 24. Global Clinical Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Clinical Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Clinical Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Research Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Research Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Research Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Research Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Research Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Research Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 41. Global Direct Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Direct Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Direct Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Third Party Distribution Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Third Party Distribution Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Third Party Distribution Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 56. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 57. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 60. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 62. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 63. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 64. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 68. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 69. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 70. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 74. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 75. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 76. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Middle East Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 80. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 81. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 87. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 88. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. ASEAN Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 93. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 94. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. GCC Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 99. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 100. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 101. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. European Union Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 105. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 106. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. BRICS Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 111. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 112. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 113. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. G7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 117. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 118. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 119. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. NATO Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 123. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 124. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 125. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 129. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 130. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 131. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 135. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 136. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 137. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 141. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 142. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 143. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 144. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 147. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 148. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 149. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. United Kingdom Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 153. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 154. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 155. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 159. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 160. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 161. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 165. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 166. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 167. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 171. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 172. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 173. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 174. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 177. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 178. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 179. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 180. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 183. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 184. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 185. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 189. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 190. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 191. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 192. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 195. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 196. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 197. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 198. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 201. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 202. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 203. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, 2017-2032 (USD Million)
TABLE 207. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radiotracer Type, 2017-2032 (USD Million)
TABLE 208. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Radioisotope, 2017-2032 (USD Million)
TABLE 209. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share, by Key Player, 2025
TABLE 213. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, Key Experts

Companies Mentioned

  • Avid Radiopharmaceuticals, Inc.
  • Bracco Imaging S.p.A.
  • Curium Pharma, LLC
  • Eli Lilly and Company
  • Fujifilm Holdings Corporation
  • GE Healthcare Limited
  • Ion Beam Applications S.A.
  • Life Molecular Imaging, Inc.
  • Navidea Biopharmaceuticals, Inc.

Related Topics

Related Reports

Radiopharmaceuticals Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Radiopharmaceuticals Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Radiopharmaceutical Synthesizer Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Radiopharmaceutical Synthesizer Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032 - Product Image

Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Radiopharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.